Comparing Addex Therapeutics (NASDAQ:ADXN) & Eton Pharmaceuticals (NASDAQ:ETON)

Eton Pharmaceuticals (NASDAQ:ETON) and Addex Therapeutics (NASDAQ:ADXN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation and dividends.

Earnings and Valuation

This table compares Eton Pharmaceuticals and Addex Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$105.59 million	16.86	-$4.60 million	$0.38	163.92
Addex Therapeutics	$29,972.00	196.07	-$8.12 million	($5.94)	-0.80

Eton Pharmaceuticals has higher revenue and earnings than Addex Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than Eton Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Eton Pharmaceuticals and Addex Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	12.02%	40.13%	12.37%
Addex Therapeutics	N/A	-134.76%	-106.00%

Volatility & Risk

Eton Pharmaceuticals has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Addex Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Eton Pharmaceuticals and Addex Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	2	0	4	0	2.33
Addex Therapeutics	1	0	0	0	1.00

Eton Pharmaceuticals currently has a consensus price target of $67.50, suggesting a potential upside of 8.36%. Given Eton Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Eton Pharmaceuticals is more favorable than Addex Therapeutics.

Insider and Institutional Ownership

27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are held by institutional investors. 16.5% of Eton Pharmaceuticals shares are held by company insiders. Comparatively, 15.0% of Addex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Eton Pharmaceuticals beats Addex Therapeutics on 12 of the 14 factors compared between the two stocks.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.